This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the approval of Enhertu as the first HER2-directed therapy in patients with HER2-low metastatic breast cancer

Ticker(s): AZN

Who's the expert?

Institution: UC San Diego Health

  • Associate professor of Clinical Medicine and Scientific Director of Inflammatory and Triple Negative Breast Cancer Program at UC San Diego Health.
  • Principal investigator of many clinical trials and is part of the national clinical operations leadership for the I-SPY-2 trial focusing on the treatment of triple negative breast cancer.
  • Has published numerous papers on the topic of metastatic breast cancer in in JAMA Oncology, Cancer Cell and Molecular Cancer Therapeutics, among others.
  • Manages over 300 patients with HER2 low breast cancer and currently prescribes Enhertu

Interview Questions

How many patients with HER2- low metastatic breast cancer do you manage?

Added By: dami_admin

On a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Enhertu in this treatment population?

Added By: dami_admin

How many breast cancer patients do you manage?  How many would you estimate are metastatic with HER-2 low status?

Added By: user1ae2bf5f

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.